Derivative spectrophotometric analysis of benzophenone (as an impurity) in phenytoin

ABSTRACT: Three simple and rapid spectrophotometric methods were developed for detection and trace determination of benzophenone (the main impurity) in phenytoin bulk powder and pharmaceutical formulations. The first method, zero-crossing first derivative spectrophotometry, depends on measuring the first derivative trough values at 257.6 nm for benzophenone. The second method, zero-crossing third derivative spectrophotometry, depends on measuring the third derivative peak values at 263.2 nm. The third method, ratio first derivative spectrophotometry, depends on measuring the peak amplitudes of the first derivative of the ratio spectra (the spectra of benzophenone divided by the spectrum of 5.0 μg/mL phenytoin solution) at 272 nm. The calibration graphs were linear over the range of 1-10 μg/mL. The detection limits of the first and the third derivative methods were found to be 0.04 μg/mL and 0.11 μg/mL and the quantitation limits were 0.13 μg/mL and 0.34 μg/mL, respectively, while for the ratio derivative method, the detection limit was 0.06 μg/mL and the quantitation limit was 0.18 μg/mL. The proposed methods were applied successfully to the assay of the studied drug in phenytoin bulk powder and certain pharmaceutical preparations. The results were statistically compared to those obtained using a polarographic method and were found to be in good agreement.     

Kinetic Spectrophotometric Determination of Ranitidine

Two spectrophotometric methods were developed for the determination of ranitidine. The first method was a kinetic spectrophotometric method based on the catalytic effect of ranitidine on the reaction between sodium azide and iodine in an aqueous solution. The calibration graph was linear from 4–24 μg/mL. The drug was determined by measuring the decrease in the absorbance of iodine at 348 nm using a fixed time method. The decrease in the absorbance after 1 minute from the initiation of the reaction was related to the concentration of drug. The detection limit of the procedure was 0.76 μg/mL. The proposed procedure was successfully utilized in the determination of the drug in pharmaceutical preparations with mean recovery in the range of 99.83 ? 101.16%. The second method is a colorimetric method, which depends on the measurement of absorbances of tris (o‐phenanthroline) iron(II) [method 2A] and tris (bipyridyl) iron(II) [method 2B] complexes at 512 nm. The complexes obeyed Beer's law over the concentration range of 2–16 μg/mL and 4–40 μg/mL for methods 2A and 2B, respectively. The developed method has been successfully applied for the determination of ranitidine in bulk drugs and pharmaceutical formulations. The common excipients and additives did not interfere in its determination.     

Spectrophotometric determination of three anti-ulcer drugs through charge-transfer complexation

A simple charge-transfer complexation method is described for the spectrophotometric assay of nizatidine, ranitidine, and famotidine. This method is based on interaction of these drugs, as n-electron donors, with 7,7,8,8-tetracyanoquinodimethane, as the pi-acceptor, in acetonitrile to give highly colored green radical anions that are measured at 840 nm. Calibration graphs for the 3 compounds are linear over the concentration ranges of 1-6 microg/mL for nizatidine and ranitidine and 1-7 microg/mL for famotidine, with correlation coefficients (n = 6) of >0.999. The conditioned stability constants and the free energy changes were measured; the values obtained were generally high and negative, respectively, suggesting highly stable complexes. The proposed method was successfully applied to the determination of the drugs in pharmaceutical preparations. The assay results were in accordance with those obtained by using reference methods.     

Determination of eprosartan mesylate and hydrochlorothiazide in tablets by derivative spectrophotometric and high-performance liquid chromatographic methods

Two new simple and selective assay methods have been presented for the analysis of eprosartan mesylate (EPR) and hydrochlorothiazide (HCT) in pharmaceutical formulations. The first method is based on first-derivative ultraviolet spectrophotometry with zero-crossing measurements at 246 and 279 nm for EPR and HCT, respectively. The assay was linear over the concentration ranges 3.0-14.0 μg/mL for EPR and 1.0-12.0 μg/mL for HCT. The quantification limits for EPR and HCT were found to be 1.148 and 0.581 μg/mL, respectively, while the detection limits were 0.344 μg/mL for EPR and 0.175 μg/mL for HCT. The second method involved isocratic reversed-phase liquid chromatography using a mobile phase composed of acetonitrile-10 mM phosphoric acid (pH 2.5) (40:60, v/v). Olmesartan was used as internal standard and the substances were detected at 272 nm. The linearity ranges were found to be 0.5-30 and 0.3-15.0 μg/mL for EPR and HCT, respectively. The limits of detection were found to be 0.121 μg/mL for EPR and 0.045 μg/mL for HCT. The limits of quantification were found to be 0.405 and 0.148 μg/mL for EPR and HCT, respectively. The proposed methods were successfully applied to the determination of commercially available tablets with a high percentage of recovery and good accuracy and precision.     

Liquid chromatographic method for the simultaneous determination of captopril,piroxicam, and amlodipine in bulk drug,pharmaceutical formulation,and human serum by programming the detector

A highly sensitive LC method with UV detection has been developed for the simultaneous determination of coadministered drugs captopril, piroxicam, and amlodipine in bulk drug, pharmaceutical formulations, and human serum at the isosbestic point (235 nm) and at individual λ_max (220, 255, and 238 nm, respectively) by programming the detector with time to match the individual analyte's chromophore, which enhanced the sensitivity with linear range. The assay involved an isocratic elution of analytes on a Bondapak C₁₈ (10 μm, 25 × 0.46 cm) column at ambient temperature using a mobile phase of methanol/water 80:20 at pH 2.9 and a flow rate of 1.0 mL/min. Linearity was found to be 0.25–25, 0.10–6.0, and 0.20–13.0 μg/mL with correlation coefficient >0.998 and detection limits of 7.39, 3.90, and 9.38 ng/mL, respectively, whereas calibration curves for wavelength‐programmed analysis were 0.10–6.0, 0.04–2.56, and 0.10–10.0 μg/mL with correlation coefficient >0.998 and detection limits of 5.79, 2.68, and 3.87 ng/mL, respectively. All the validated parameters were in the acceptable range. The recovery of drugs was 99.32–100.39 and 98.65–101.96% in pharmaceutical formulation and human serum, respectively, at the isosbestic point and at individual λ_max. This method is applicable for the analysis of drugs in bulk drug, tablets, serum, and in clinical samples without interference of excipients or endogenous serum components.     

Validation of a high-performance chromatographic method for determination of cefotaxime in biological samples

An analytical method for detecting and quantifying cefotaxime in plasma and several tissues is described. The method was developed and validated using plasma and tissues of rats. The samples were analyzed by reversed phase liquid chromatography (HPLC) with UV detection (254 nm). Calibration graphs showed a linear correlation (r > 0.999) over the concentration ranges of 0.5–200 μg/mL and 1.25–25 μg/g for plasma and tissues, respectively. The recovery of cefotaxime from plasma standards prepared at the concentrations of 25 μg/mL and 100 μg/mL was 98.5 ± 3.5% and 101.8 ± 2.2%, respectively. The recovery of cefotaxime from tissue standards of liver, fat and muscle, prepared at the concentration of 10 μg/g was: 89.8 ± 1.2% (liver), 103.9 ± 6.5% (fat) and 97.8 ± 2.1% (muscle). The detection (LOD) and quantitation (LOQ) limits for plasma samples were established at 0.11 μg/mL and 0.49 μg/mL, respectively. The values of these limits for tissues samples were approximately 2.5 times higher: 0.3 μg/g (LOD) and 1.25 μg/g (LOQ). For plasma samples, the deviation of the observed concentration from the nominal concentration was less than 5% and the coefficient of variation for within-day and between-day assays was less than 6% and 12%, respectively. The method was used in a pharmacokinetic study of cefotaxime in the rat and the mean values of the pharmacokinetic parameters are given.     

Spectrophotometric Determination of Some Antiulcerative Drugs in Pharmaceutical Dosages

The aim of this work is to develop cheap, safe, rapid, reliable and reproducible spectrophotometric method for the assay of some antiulcerative drugs namely Omedar, Nadine and Rantag in their pharmaceutical dosages, using methyl red (MR) as a chromogenic reagent. The proposed method is based on the reaction of each of the three drugs with MR at pH 3.0. The optimum analytical variables have been investigated carefully. The maximum absorbance was obtained at 405 nm with absorptivity of 1.35 × 10⁴ L/mol cm. Beer’s law is obeyed in the range of concentration of 0.5–15 μg/mL for ranitidine (active ingredient) content in the studied drugs. The limits of detection and quantification of the drug active ingredient were 0.05 and 0.13 μg/mL, respectively, with a linear regression correlation coefficient of 0.998, and recovery was in the range 99.91–100.48%. Effects of pH, temperature, standing time and MR concentration on the determination of ranitidine hydrochloride of the drugs have been examined. This method is simple and can be used for the determination of ranitidine in the pharmaceutical dosages of antiulcerative drugs.     

Kinetic spectrophotometric method for the determination of ranitidine and nizatidine in pharmaceuticals

An accurate and simple kinetic method is described for the determination of ranitidine and nizatidine in pure form and in pharmaceuticals. The method is based on the reaction of the compounds with 7-chloro-4-nitrobenz-2-oxa-1,3-diazole in pH 7.4 borate buffer at 60 degrees C for a fixed time of 25 min for both compounds. The absorbance of the reaction product is measured at 495 nm for ranitidine and nizatidine. Calibration graphs were linear over the concentration range of 2-20 microg/mL, with limits of detection of 0.13 (3.7 x 10(-7) M) and 0.25 microg/mL (7.5 x 10(-7) M) for ranitidine and nizatidine, respectively. The proposed method was applied successfully to the determination of ranitidine in tablets and ampoules with average recoveries of 100.26+/-0.69 and 100.29+/-0.59%, respectively, and to the determination of nizatidine in capsules with an average recovery of 104.26+/-0.44%. The results obtained are in good agreement with those obtained by the other methods used for comparison. A proposal of the reaction pathway is also presented.     

Determination of ranitidine, nizatidine, and cimetidine by a sensitive fluorescent probe

A validated, simple, and sensitive fluorescence quenching method for the determination of ranitidine, nizatidine, and cimetidine in tablets and biological fluids is presented. This is the first single fluorescence method reported for the analysis of all three H(2) antagonists. The competitive reaction between the investigated drug and the palmatine probe for the occupancy of the cucurbit[7]uril (CB[7]) cavity was studied using spectrofluorometry. CB[7] was found to react with the probe to form a stable complex. The fluorescence intensity of the complex was also enhanced greatly. However, the addition of the drug dramatically quenched the fluorescence intensity of the complex. Accordingly, a new fluorescence quenching method for the determination of the studied drugs was established. The different experimental parameters affecting the fluorescence quenching intensity were studied carefully. At optimum reaction conditions, the rectilinear calibration graphs between the fluorescence quenching values (ΔF) and the medicament concentration were obtained in the concentration range of 0.04-1.9 μg mL(-1) for the investigated drugs. The limits of detection ranged from 0.013 to 0.030 μg mL(-1) at 495 nm using an excitation wavelength of 343 nm. The proposed method can be used for the determination of the three H(2) antagonists in raw materials, dosage forms and biological fluids.     

Head-column field-amplified sample stacking in capillary electrophoresis for the determination of cimetidine, famotidine, nizatidine, and ranitidine-HCl in plasma.

In this study, low concentrations of histamine2-receptor (H2-)antagonists were effected across a water plug, with separation taking place in a binary buffer comprising ethylene glycol and NaH2PO4 (pH 5.0), and detection at 214 nm. Liquid-liquid extraction with ethyl acetate- isopropanol is shown to provide extracts that are sufficiently clean. The calibration curves were linear over a concentration range of 0.1-2.00 microg/mL cimetidine, 0.2-5.0 microg/mL ranitidine-HCl, 0.3-5.0 microg/mL nizatidine, and 0.1-3.0 microg/mL famotidine. Mean recoveries were > 82%, while the intra- and interday relative standard deviations (RSDs) and relative errors (REs) were all < 13%. The method is sensitive with a detection limit of 3 ng/mL cimetidine, 30 ng/mL ranitidine HCl, 50 ng/mL nizatidine and 10 ng/mL famotidine (S/N = 3, electric-driven injection 90 s). This newly developed capillary electrophoresis (CE) method was applied for the determination of analytes extracted from plasma taken from a volunteer dosing a cimetidine, ranitidine, and nizatidine tablet simultaneously. These three H2-antagonists can be detected in real samples by this method, excluding the low dosing of famotidine tablet.     

Determination of flurbiprofen in pharmaceutical preparations by GC–MS

This article describes a gas chromatography–mass spectrometry (GC–MS) method for the determination of flurbiprofen in pharmaceutical preparations. The method is based on the derivatization of flurbiprofen with N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA). For GC–MS, electron ionization mode (EI = 70 eV) and selected ion monitoring (SIM) mode were used for quantitative analysis (m/z 180 for flurbiprofen). Calibration curve was linear between the concentration range of 0.25–5.0 μg/mL. Intra- and inter-day precision values for flurbiprofen were less than 3.64, and accuracy (relative error) was better than 2.67%. The mean recovery of flurbiprofen was 99.4% for pharmaceutical preparations. The limits of detection and quantification of flurbiprofen were 0.05 and 0.15 μg/mL, respectively. No interference was found from tablet excipients at the selected assay conditions. Also, the method was applied for the quality control of five commercial flurbiprofen dosage forms to quantify the drug and to check the formulation content uniformity.     

Spectrophotometric determination of glimepiride in pharmaceutical preparations based on the formation of charge-transfer and ion-pair complexes

Two rapid, simple, accurate and sensitive spectrophotometric methods were developed for the determination of glimepiride in pharmaceutical preparations. The first method was based on the formation of a charge-transfer complex of the drug, as n-electron donor, with 7,7,8,8-tetracyanoquinodimethane (TCNQ), as π-acceptor. The second method was based on the formation of ion-pair complexes between the examined drug and bromothymol blue (BTB). The proposed methods were validated for linearity, limit of detection, limit of quantification, precision, accuracy, robustness and specificity. The calibration was linear over the concentration range of 10–80 and 20–120 μg/mL for methods I and II, respectively. The limits of detection were 2.6 and 2.8 μg/mL. The proposed methods were applied to the determination of the drug in pharmaceutical preparations. The results obtained were in good agreement with those obtained using the reference method (HPLC). There was no significant difference in the accuracy and precision as revealed by the accepted values of t- and F-tests, respectively.     

Simultaneous HPLC determination of thiocolchicoside and glafenine as well as thiocolchicoside and floctafenine in their combined dosage forms

Sensitive and accurate high-performance liquid chromatographic methods have been developed for the simultaneous determination of thiocolchicoside (TC)-glafenine (GF) (Mix I) and thiocolchicoside-floctafenine (FN) (Mix II) in their pharmaceutical formulations. The analysis for both mixtures was performed using 250 mm × 4.6 mm i.d., 5 μm particle size C18 Waters Symmetry column. The mobile phase consisted of methanol-0.035 M phosphate buffer (50:50, v/v) of pH 4.5 for Mix I and methanol-0.03 M phosphate buffer (70:30, v/v) of pH 4 for Mix II with flow rate of 1 mL/min and UV detection at 400 nm in both cases. The calibration plots were rectilinear over the concentration range of 0.2-2 μg/mL for TC in both mixtures and 20-200 μg/mL for each of GF and FN . The limits of detection for TC and GF were 0.05 μg/mL and 0.62 μg/mL, respectively, and for TC and FN were 0.02 μg/mL and 0.70 μg/mL, respectively. Additionally, the proposed methods were successfully applied to their combined tablets with average percentage recoveries of 100.35 ± 0.61 and 100.57 ± 0.72% for TC and GF respectively and for TC and FN the percentage recoveries were 101.2 ± 0.72 and 100.36 ± 0.67%, respectively. The results obtained were favorably compared with those given using the comparison methods.     

Development and validation of RP-HPLC,HPTLC and UV-visible spectrophotometric methods for simultaneous estimation of alprazolam and propranolol hydrochloride in their combined dosage form

Three accurate, sensitive and reproducible methods are described for the quantitative determination of alprazolam (ALP) and propranolol hydrochloride (PNL) in their combined dosage form. The first method involves an RP-HPLC separation on the C₁₈ column using acetonitrile-25 mM ammonium acetate buffer and 0.2% triethylamine (pH of buffer adjusted to 4 with glacial acetic acid) in the ratio of 35: 65 (v/v) as mobile phase. Symmetrical peaks with good separation, ALP at 9.3 min and PNL at 3.5 min, were achieved. Quantification was done with photo diode array detection at 255 nm over the concentration ranges of 0.5–50 and 10–250 μg/mL for ALP and PNL, respectively. The second method is based on the separation of drugs by HPTLC using chloroform-methanol-ammonia 7: 0.8: 0.1 (v/v/v) as mobile phase. Quantification was achieved using UV detection at 248 nm over the concentration range of 100–600 ng/spot and 5–30 μg/spot for ALP and PNL, respectively. The third method involves dual wavelength UV-visible spectrophotometric method. It is based on the determination of PNL at 319.4 nm using its absorptivity value and ALP at 258.2 nm after deduction of absorbance due to PNL. Quantification was achieved over the concentration range of 1–40 and 80–200 μg/mL for ALP and PNL, respectively. All methods were validated according to ICH guidelines and successively applied to marketed pharmaceutical formulation, and the results of all three methods were compared statistically as well. No interference from the tablet excipients was found.     

RP-HPLC method for simultaneous estimation of lamivudine, tenofovir disoproxil fumarate and efavirenz in tablet formulation

A simple, rapid, and precise reversed-phase high-performance liquid chromatographic method for the simultaneous determination of lamivudine, tenofovir disoproxil fumarate and efavirenz in bulk and tablet dosage form has been developed and validated. Chromatography was performed on a 150 mm × 4.6 mm i.d., 5-μm particle, Phenomenex Luna C₁₈ column with 30: 45: 25 (v/v/v) acetonitrile: methanol: water as mobile phase at a flow rate of 0.5 mL/min. UV detection was done at 258 nm; lamivudine, tenofovir disoproxil fumarate and efavirenz were eluted with retention times of 3.27, 4.58 and 10.90 min, respectively. The method was validated in accordance with ICH guidelines. Validation revealed the method is specific, rapid, accurate, precise, reliable and reproducible. Calibration plots were linear over the concentration ranges 1–6 μg/mL for lamivudine and tenofovir disoproxil fumarate and 2–12 μg/mL for efavirenz. Limits of detection were 0.05, 0.09 and 0.11 μg/mL and limits of quantification were 0.15, 0.28 and 0.34 μg/mL for lamivudine, tenofovir disoproxil fumarate and efavirenz, respectively. The high recovery and low coefficients of variation confirm the suitability of the method for the simultaneous determination of these three drugs in bulk and tablets.     

Determination of glucosamine and carisoprodol in pharmaceutical formulations by LC with pre-column derivatization and UV detection

A simple and reliable precolumn derivatization liquid chromatography method with ultraviolet detection has been developed and validated for the analysis of glucosamine (GS) in various dietary supplement formulations and raw materials. Additionally, the proposed method was used for analysis of carisoprodol (CR) found in ternary mixture with paracetamol (PR) and caffeine (CF). The linearity ranges were 1-100 μg/mL for GS, 1-150 μg/mL for CR, PR and CF. Derivatization was used with 1,2-naphthoquinone-4-sulphonic acid sodium salt in the presence of borate buffer. Chromatographic separation of GS-naphthoquinone derivative was achieved by using a mixture of acetonitrile and water (pH 7.3 adjusted with 0.1 M NaOH) in the ratio 10:90, v/v and flow-rate of 1.0 mL/min. UV detection was carried out at 280 nm. For PR, CF, and CR-naphthoquinone derivative, the chromatographic separation was achieved by using mixture of acetonitrile and 20 mM KH(2)PO(4) (pH 3.0 adjusted with phosphoric acid) in the ratio 20:80, v/v and flow-rate of 1.0 mL/min. UV detection was carried out at 275 nm. The limits of detection were 37.2, 35.9, 30.4 and 40.0 ng/mL for GS, CR, PR and CF, respectively.     

Kinetic and Spectrophotometric Determination of Thioctic Acid in Bulk and Pharmaceutical Formulations

Three simple and sensitive spectrophotometric methods were developed for the determination of thioctic acid in bulk and in its pharmaceutical preparations using iron(III) as an oxidizing agent. Method A is based on kinetic investigation of oxidation reaction of the drug with iron(III) and a subsequent chelation of the produced iron(II) with ferricyanide to form prussian blue colored product at room temperature for a fixed time of 15 minutes at 750 nm. Methods B and C are based on oxidation of the studied drug with iron(III). The equivalent iron(II) produced is allowed to react with either o‐phenanthroline or bipyridyl to give colored species measurable at 510, 522 nm, respectively. Regression analysis of Beer‐Lambert plots showed a good correlation in the concentration ranges of 0.4–4 μg/mL with a detection limit of 0.095 μg/mL for method A and 0.5–5 μg/mL with detection limits 0.137 and 0.127 for method B and C, respectively. The three methods were successfully applied for the determination of the drug in its dosage forms. The percentage recoveries were 99.88 ± 1.40, 99.98 ± 1.26 and 100.64 ± 1.07, respectively.     

Simultaneous determination of chlordiazepoxide and selected antidepressants using CZE

A simple CE method was developed and validated for the simultaneous determination of chlordiazepoxide (CHL), amitriptyline, and nortriptyline (mixture I) or the determination of CHL and imipramine (mixture II) using the same BGE. Sertraline and amitriptyline were used as internal standards for the first and second mixtures, respectively. The method allows amitriptyline to be completely separated from its impurity and main metabolite nortriptyline, which can be quantified from 0.2 μg/mL. The separation was achieved using 20 mM potassium phosphate buffer pH 5 containing 12 mM β‐cyclodextrin and 1 mM carboxymethyl‐β‐cyclodextrin. UV detection was performed at 200 nm and a voltage of 15 kV was applied on an uncoated fused‐silica capillary at 25°C. These experimental conditions allowed separation of the compounds to be obtained in 7 min. Calibration graphs proved the linearity up to 40 μg/mL for CHL, up to 100 μg/mL for amitriptyline and imipramine, and up to 5 μg/mL for nortriptyline. The accuracy and precision of the method have been determined by analyzing synthetic mixtures and pharmaceutical formulations. The analytical results were quite good in all cases indicating that the method was linear, sensitive, precise, accurate, and selective for both mixtures.     

Determination of acysole in whole blood by high-performance liquid chromatography

A method is developed for the determination of a carbon monoxide antidote acysole in whole blood using hydrophilic interaction high-performance liquid chromatography with UV detection. Two methods were used for sample preparation: protein precipitation with acetonitrile and solid-phase extraction (SPE) with an acysole recovery of 95.8 and 89.8%, respectively. Chromatographic determination was performed in the isocratic mode on a Nucleodur HILIC column and with an acetonitrile: water 95: 5 mobile phase at 225 nm. The calibration graphs are linear in the concentration range 0.056–111.1 μg/mL. The limits of detection and determination of acysole were 0.050 and 0.120 μg/mL after protein precipitation with acetonitrile and 0.071 and 0.169 μg/mL with SPE, respectively.     

Validated RP-HPLC method for determination of permethrin in bulk and topical preparations using UV-vis detector

An isocratic reversed-phase high-performance liquid chromatographic method for the estimation of permethrin in raw materials and pharmaceutical topical preparations has been devised and validated. The chromatographic analysis was performed on a 5 μm particle C-18 Nucleosil (Macherey-Nagel, Germany) column (250 × 4.6 mm). Mobile phase consisted of methanol and 0.025 mM Phosphoric acid (85:15 v/v) at a flow rate of 1.5 mL/min. UV detection was performed at 272 nm and peaks were identified with retention times as compared with standards. The limit of detection was 1.782 μg/mL, while limit of quantitation was 48.0 μg/mL. The calibration was linear in a concentration range of 48.0-5000 μg/mL with correlation coefficient of 0.999978. Regression equation was absorbance =2833.23 × concentration(μg/mL) + 19.1045 with variance of the response variable, S(yx)(2), calculated to be 1.75328 (six degrees of freedom). The method was validated as per ICH guidelines and USP requirements and found advantageous for the routine analysis of the drug in pharmaceutical formulations and in pharmaceutical investigations involving permethrin.